Abstract Coronavirus Disease‐19 (COVID‐19) is an infectious disease caused by severe
acute respiratory syndrome‐coronaviruses‐2 (SARS‐CoV‐2), a highly pathogenic and …

Coronavirus disease-19 (COVID-19) emerged in December 2019 and quickly spread, giving
rise to a pandemic crisis. Therefore, it triggered tireless efforts to identify the mechanisms of …

Background Remdesivir, molnupiravir, and nirmatrelvir/ritonavir are three antiviral agents
approved by FDA emergency authorization for treating mild to moderate symptomatic COVID …

Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the highly
pathogenic and highly transmissible human coronavirus that is the causative agent for the …

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a highly
infectious positive RNA virus, has spread from its epicenter to other countries with increased …

The recent outbreak of COVID-19 has increased hospital admissions, which could elevate
the risk of nosocomial infections, such as A. baumannii and P. aeruginosa infections …

The COVID-19 pandemic exposed the lack of antiviral agents available for human use, while
the complexity of the physiological changes caused by coronavirus (SARS-CoV-2) imposed …

CONCLUSIONS Interventions that are part of comprehensive pulmonary rehabilitation
approaches may benefit dyspnea and exercise tolerance in adults with COVID-19 and PCC …

Abstract Background Clinical practice guidelines (CPGs) are statements that should be
rigorously developed to guide clinicians' decision-making. However, given the scarce …

Treatment options for Coronavirus Disease 2019 (COVID-19) remain limited, and the option
of repurposing approved drugs with promising medicinal properties is of increasing interest …